BRPI0913485A2 - medicamentos anticâncer e usos relacionados para melanoma maligno metastático e outros cânceres. - Google Patents

medicamentos anticâncer e usos relacionados para melanoma maligno metastático e outros cânceres.

Info

Publication number
BRPI0913485A2
BRPI0913485A2 BRPI0913485A BRPI0913485A BRPI0913485A2 BR PI0913485 A2 BRPI0913485 A2 BR PI0913485A2 BR PI0913485 A BRPI0913485 A BR PI0913485A BR PI0913485 A BRPI0913485 A BR PI0913485A BR PI0913485 A2 BRPI0913485 A2 BR PI0913485A2
Authority
BR
Brazil
Prior art keywords
cancers
malignant melanoma
metastatic malignant
related uses
anticancer medicines
Prior art date
Application number
BRPI0913485A
Other languages
English (en)
Portuguese (pt)
Inventor
Bhupathiraju Kiran
Gokaraju Ganga Raju
Gokaraju Rama Raju
Golakoti Trimurtulu
Kasina Sudhakar
Krishanu Sengupta
Somepalli Venkateswarlu
Original Assignee
Kasina Laila Innova Pharmaceuticals Private Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kasina Laila Innova Pharmaceuticals Private Ltd filed Critical Kasina Laila Innova Pharmaceuticals Private Ltd
Publication of BRPI0913485A2 publication Critical patent/BRPI0913485A2/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D333/00Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D333/00Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D333/40Thiophene-2-carboxylic acid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
BRPI0913485A 2008-09-15 2009-09-14 medicamentos anticâncer e usos relacionados para melanoma maligno metastático e outros cânceres. BRPI0913485A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN2230CH2008 2008-09-15
PCT/IN2009/000504 WO2010029577A2 (en) 2008-09-15 2009-09-14 Anti-cancer drugs and uses relating thereto for metastatic malignant melanoma and other cancers

Publications (1)

Publication Number Publication Date
BRPI0913485A2 true BRPI0913485A2 (pt) 2016-06-07

Family

ID=41565903

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0913485A BRPI0913485A2 (pt) 2008-09-15 2009-09-14 medicamentos anticâncer e usos relacionados para melanoma maligno metastático e outros cânceres.

Country Status (11)

Country Link
US (1) US8258119B2 (https=)
EP (1) EP2324006B1 (https=)
JP (1) JP2012502900A (https=)
KR (1) KR20110063537A (https=)
CN (1) CN102149703B (https=)
AU (1) AU2009290365B2 (https=)
BR (1) BRPI0913485A2 (https=)
CA (1) CA2736732A1 (https=)
IL (1) IL211366A0 (https=)
NZ (1) NZ591394A (https=)
WO (1) WO2010029577A2 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2424351B1 (en) * 2009-04-27 2015-10-21 Kasina Laila Innova Pharmaceuticals Private Ltd. Anti-cancer drugs, and uses relating for malignant melanoma and other cancers
NO2686520T3 (https=) 2011-06-06 2018-03-17
WO2012170439A1 (en) * 2011-06-06 2012-12-13 The Ohio State University Methods for stabilizing hypoxia inducible factor-2 alpha as a method for treating cancer
JP2016521747A (ja) 2013-06-13 2016-07-25 アケビア セラピューティクス インコーポレイテッドAkebia Therapeutics Inc. 貧血治療のための組成物及び方法
US9593095B2 (en) 2013-06-14 2017-03-14 Duke University Methods for the treatment of bacterial infections
DE112014006766T5 (de) * 2014-06-27 2017-04-27 Ecole Polytechnique Federale De Lausanne (Epfl) Epfl-Tto Herstellung und medizinische Verwendung von Triazenen
US10150734B2 (en) 2015-01-23 2018-12-11 Akebia Therapeutics, Inc. Solid forms of 2-(5-(3-fluorophenyl)-3-hydroxypicolinamido)acetic acid, compositions, and uses thereof
US11324734B2 (en) 2015-04-01 2022-05-10 Akebia Therapeutics, Inc. Compositions and methods for treating anemia
AU2016265922B2 (en) 2015-05-18 2021-05-20 Syn-Nat Products Enterprise LLC A pharmaceutical co-crystal and use thereof
BR112017027277A2 (pt) * 2015-06-19 2018-09-04 Syn Nat Products Entpr Llc ?método para o tratamento ou prevenção de uma doença e métodos para matar uma célula?
BR112017027285A2 (pt) 2015-06-19 2018-09-11 Syn Nat Products Entpr Llc ?cocristal, composição farmacêutica e método para o tratamento de uma doença?
US10428099B2 (en) 2015-06-25 2019-10-01 Syn-Nat Products Enterprise LLC Pharmaceutical co-crystal composition and use thereof
US11713298B2 (en) 2018-05-09 2023-08-01 Akebia Therapeutics, Inc. Process for preparing 2-[[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino]acetic acid
WO2021117767A1 (ja) 2019-12-10 2021-06-17 田辺三菱製薬株式会社 含窒素ヘテロアリールカルボキサミド酢酸誘導体の製造方法
KR102648781B1 (ko) 2021-11-09 2024-03-19 국립공주대학교 산학협력단 항암 활성을 갖는 인데노피라졸론 유도체 화합물, 그의 제조방법 및 그의 용도

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1020641B (de) 1955-10-15 1957-12-12 Basf Ag Verfahren zur Herstellung von Derivaten der 3-Oxythiophen-2-carbonsaeure
CA968347A (en) * 1968-09-09 1975-05-27 John F. Gerster Substituted pyrazoles and process

Also Published As

Publication number Publication date
CN102149703A (zh) 2011-08-10
US20100068178A1 (en) 2010-03-18
EP2324006A2 (en) 2011-05-25
WO2010029577A3 (en) 2010-05-06
AU2009290365A1 (en) 2010-03-18
WO2010029577A2 (en) 2010-03-18
JP2012502900A (ja) 2012-02-02
KR20110063537A (ko) 2011-06-10
NZ591394A (en) 2013-03-28
US8258119B2 (en) 2012-09-04
EP2324006B1 (en) 2014-08-13
IL211366A0 (en) 2011-04-28
CN102149703B (zh) 2014-09-10
CA2736732A1 (en) 2010-03-18
AU2009290365B2 (en) 2014-08-14

Similar Documents

Publication Publication Date Title
BRPI0913485A2 (pt) medicamentos anticâncer e usos relacionados para melanoma maligno metastático e outros cânceres.
BRPI1006651A2 (pt) Medicamentos anticancer e usos relacionados para melanome maligno e outros canceres
HUS2300018I1 (hu) Rákellenes hatású kinoli-8-szulfonamid-származékok
PT3195873T (pt) Nova imunoterapia para vários tumores, incluindo cancro gastrointestinal e gástrico
DK2121731T3 (da) Peptidvacciner til cancere som udtrykker tumor-associerede antigener
BRPI0818320A2 (pt) composição para tratamento de câncer de próstata (pca)
BRPI0808032A2 (pt) Processos para preparar hidroxipivalinaldeído e para preparar neopentil glicol.
PL3069728T3 (pl) Nowa immunoterapia względem wielu nowotworów, w tym guzów neuronalnych i guzów mózgu
RU2448708C3 (ru) Противоопухолевое средство против рака щитовидной железы
BRPI0821276A2 (pt) Produto, e, uso do produto
PT2456889E (pt) Marcadores para o cancro do endométrio
BRPI1010918A2 (pt) documento de segurança compreendendo quelatos luminescentes.
FR2947435B1 (fr) Article cosmetique incluant une structure multicouche electrochromique.
IL220386B (en) Compositions for the liquidation of tumors and uses thereof
WO2011139721A8 (en) Cancer biomarkers and methods of use thereof
PT2162149E (pt) Vacina para a prevenção da recaída do cancro da mama
BRPI0816150A2 (pt) genes relacionados com câncer, cdca5, eph47, stk31 e w-dhd1.
BRPI0924981A2 (pt) vacinas para câncer cervical.
DK2257301T3 (da) Immunterapi baseret på allogene cancerceller.
EP2147122A4 (en) ENZYMATIC TUMOR THERAPY
BRPI0922849A2 (pt) vacina para a prevenção de recorrência de câncer de mama
FI20075158L (fi) Muunneltuja hydroksipolymeerikonjugaatteja, joilla on syöpäsoluja tappava vaikutus
EP2502627A4 (en) ANTI CANCER AGENTS
FR2925235B1 (fr) Socle antivibratile multi-format
EP2105140A4 (en) CANCER AGENT

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2385 DE 20-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.